Molnlycke

Mölnlycke, a Swedish pharmaceutical preparation manufacturer, reported total emissions of approximately 533,096,000 kg CO2e in 2025. This includes Scope 1 emissions of around 47,896,000 kg CO2e, Scope 2 market-based emissions of approximately 1,935,000 kg CO2e, and Scope 3 emissions totalling about 483,265,000 kg CO2e. Key contributors to their Scope 3 emissions were purchased goods and services (approximately 295,119,000 kg CO2e) and capital goods (around 78,101,000 kg CO2e).

The company has set ambitious climate commitments, with near-term Science Based Targets (SBTi) in place. Mölnlycke aims to reduce absolute Scope 1 and 2 greenhouse gas emissions by 50% by 2030, using 2021 as the base year. They also commit to increasing active annual sourcing of renewable electricity from 23% in 2021 to 100% by the end of 2024 and maintaining 100% renewable electricity sourcing through 2030. Furthermore, Mölnlycke is targeting a 20% reduction in absolute Scope 3 GHG emissions from purchased goods and services, fuel and energy-related activities, upstream transportation and distribution, and waste generated in operations by 2028, against a 2021 baseline. The company also states that 63% of its suppliers by emissions covering purchased goods and services, capital goods, and upstream transportation and distribution, will have science-based targets by 2028.

For the long-term, Mölnlycke Health Care AB is committed to achieving net-zero greenhouse gas emissions across its value chain by 2050, including a 90% reduction in absolute Scope 1 and 2 GHG emissions by 2050 from a 2021 base year, and a 97% reduction in Scope 3 GHG emissions per tonne of sold product within the same timeframe. These targets are consistent with reductions required to keep global warming to 1.5°C.